{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001836564","name":"Valneva SE","summary":"Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Its commercial products include IXIARO (Japanese encephalitis vaccine), DUKORAL (cholera/traveler's diarrhea vaccine), and IXCHIQ (chikungunya vaccine). Its lead pipeline candidate is VLA15, a Lyme disease vaccine developed in partnership with Pfizer, currently in Phase 3 clinical trials.","people":[],"products":[{"name":"IXIARO","type":"service","description":"Vaccine against Japanese encephalitis, marketed primarily to travelers to endemic regions."},{"name":"DUKORAL","type":"service","description":"Vaccine against cholera and traveler's diarrhea, marketed primarily to travelers to endemic regions."},{"name":"IXCHIQ","type":"service","description":"Chikungunya vaccine; continued approval conditioned on completion of post-marketing clinical trials including Phase 3 and 4."},{"name":"VLA15","type":"service","description":"Lyme disease vaccine candidate in Phase 3 pivotal efficacy trial (VALOR) conducted by partner Pfizer; potential approval sought in 2026."}],"partnerships":[{"partner_name":"Pfizer","partnership_type":"development","description":"Partner conducting Phase 3 VALOR trial for Lyme disease vaccine VLA15; responsible for regulatory applications and commercialization.","start_date":null},{"partner_name":"Pharmakon Advisors, LP","partnership_type":"strategic","description":"Lender providing senior term loan facility of up to $500 million under Loan Agreement signed October 2025.","start_date":null},{"partner_name":"Scottish Enterprise","partnership_type":"strategic","description":"Provided two grants worth up to 20 million GBP to Valneva Scotland for COVID-19 vaccine and other vaccine candidate manufacturing R&D.","start_date":null},{"partner_name":"Deerfield Management","partnership_type":"strategic","description":"Previous lender repaid in full in October 2025 using proceeds from Pharmakon loan and cash on hand.","start_date":null},{"partner_name":"OrbiMed","partnership_type":"strategic","description":"Previous lender repaid in full in October 2025 using proceeds from Pharmakon loan and cash on hand.","start_date":null}],"affiliations":[],"origin":{"leaf":"e655b5feb9bcd9fb83566b0d807881823faa85181368dfdc2d179a0fea8f94c8","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"9cbee2faecda85b2a87ae391c9f935175a98e58ba1c364f42872f0af1af5bf1c","parent":"55233c04dcc5e3a375cc335754ca27798cbc14f664901a63d12253a2c4c00353","source":"0001628280-26-018808","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":350,"hourly_limit":500,"remaining":150,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}